- FDA 510 (K), EUA, ISO-13485 Quality System, FDA registered manufacturing in-house, Ready to go!
- 5.9 million patients on oxygen in the U.S. alone growing to over 7 million patients in 2023.
- Protected by 7 U.S. Patents, more pending, foreign patents pending.
- Experienced team with a history of success, from concept through acquisition. CEO has 28 patents
Founded in 2014, Dynaris has developed a new standard in oxygen delivery devices. Its patented and FDA Cleared Apogee and cannula are the first in a line of products designed to improve patient health, eliminate oxygen waste, reduce prescription costs, and provide a more comfortable therapeutic experience.
Dynaris is aiming for sales of $300,000,000/year or more in five years. Additional product offerings are expected to grow sales significantly beyond that figure. These projections cannot be guaranteed.